Interestingly, Figure 2A presents that the longer follow-up confirmed our previous findings [16] that a significantly higher incidence of disease relapse is observed in breast cancer patients with higher pre-treatment levels of heparanase compared to lower pre-treatment levels counterparts (log-rank p = 0.0431). This evidence concerns the gene HPSE and breast cancer.